Marco Tuccori, Francesco Lapi, Arianna Testi, Daniela Coli, Ugo Moretti, Alfredo Vannacci, Domenico Motola, Francesco Salvo, Alma Lisa Rivolta, Corrado Blandizzi, Alessandro Mugelli, Mario Del Tacca
BACKGROUND: The inhibitors of HMG-CoA reductase ('statins') are widely prescribed hypolipidaemic drugs, which have been evaluated in several clinical trials involving hundreds of thousands of patients. From a safety perspective, both clinical trials and post-marketing surveillance have demonstrated that statins are generally well tolerated, with rare serious adverse drug reactions (ADRs) that affect mainly muscle, liver and kidney. However, recent interest has been focused on a potential risk of psychiatric ADRs associated with statins, including memory loss, depression, suicidality, aggression and antisocial behaviour...
2008: Drug Safety: An International Journal of Medical Toxicology and Drug Experience